1999
DOI: 10.1038/sj.bmt.1701599
|View full text |Cite
|
Sign up to set email alerts
|

Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY

Abstract: Summary:The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells (PBSC) in patients with metastatic breast cancer (n = 66). A phase I trial of CY 2, 3 or 4 g/m 2 with docetaxel 100 mg/m 2 , in consecutive cohorts of four patients each, did not reveal any dose-limiting toxicities and subsequent patients were randomized to receive 3 or 4 g/m 2 of CY. The median yield of CD34 ؉ cells from all patients was 11.06 ؋ 10 6 /kg… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

2
4
0

Year Published

2000
2000
2007
2007

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 28 publications
(29 reference statements)
2
4
0
Order By: Relevance
“…Our results demonstrate superiority of doxetaxel combined with GCSF when compared with G-CSF alone. This regimen also compares favorably with recently reported results using high doses of cyclophosphamide in addition to docetaxel and G-CSF (17). Previous studies have documented that another taxane, paclitaxel, is effective in mobilizing PBSCs in conjunction with G-CSF, and improves PBSC mobilization when added to high-dose cyclophosphamide (18).…”
Section: Discussionsupporting
confidence: 64%
“…Our results demonstrate superiority of doxetaxel combined with GCSF when compared with G-CSF alone. This regimen also compares favorably with recently reported results using high doses of cyclophosphamide in addition to docetaxel and G-CSF (17). Previous studies have documented that another taxane, paclitaxel, is effective in mobilizing PBSCs in conjunction with G-CSF, and improves PBSC mobilization when added to high-dose cyclophosphamide (18).…”
Section: Discussionsupporting
confidence: 64%
“…Febrile neutropenia occurred in only four patients (36%). This finding compares favorably with those of studies of high-dose cyclophosphamide 38 and of other chemotherapy-filgrastim mobilization regimens; [39][40][41] in those reports rates of febrile neutropenia ranged from 20% to 100%.…”
Section: Discussionsupporting
confidence: 45%
“…Other investigators have examined the ability of docetaxel to mobilize CD34 ϩ cells when used in combination with either cyclophosphamide 22 or an anthracycline. 23 Taken together, docetaxel-based regimens appear to very effective to mobilise CD34 ϩ cells.…”
Section: Discussionmentioning
confidence: 99%